The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for Advancing Innovation (CAI) have partnered to launch a “first of a kind” Business Plan and Start-Up Challenge for Breast Cancer (BC) inventions that have high commercial viability and are important to public health. This challenge will accelerate the commercialization of Federal agency and AF grantee BC inventions, spur economic growth, and provide Universities a platform to further develop their entrepreneurship learning portfolio.Continue reading
The Call for Sessions opens September 5th for the
in San Diego, June 23-26, 2014.
Education enhancements in 2014 include: streamlined session tracks organized by role in the industry and featuring international representation among panels; specialty forums with cohesive content and targeted networking receptions.
- Basic Research & Discovery
- Business Development & Financing
- Clinical Trials & Product Testing
- Industrial Bioproducts
- Intellectual Property
- Manufacturing, Distribution & Operations
- Market Access & Commercialization
- Regulatory Review & Approval
- Specialty Forums on personalized medicine, agriculture technologies, vaccines, and transformational research
Start planning today: session proposals will be accepted Thursday, September 5 through Thursday, October 3, 2013.
How to develop our suggestion:
- Review the list of tracks and topic area suggestions to determine which topics are relevant and pressing
- Talk with colleagues and industry contacts about your idea; brainstorm potential speakers
- Use the Session Proposal Guide for step-by-step tips to maneuver the online submission process
Please note, proposals for the International Market Briefings (IMB) Track will be accepted separately October 14 – November 4, 2013.
With the 2014 BIO International Convention being held in San Diego, this is a great opportunity to show the world what Arizona has to offer.
QUESTIONS? If you have any questions about your topic, how to submit, etc. Email BIO at firstname.lastname@example.org.
Mission3 is looking for a Development Engineer to join their teamContinue reading
In the three months since Chandler, Arizona based Insys Therapeutics had its initial public offering Insys stock has been on the rise with a gain of over 120% from its original offering price. Continue reading
STEM education is one of the hottest topics in education and economics today. To be globally competitive in the future, our nation and our industry needs to encourage and inspire students to pursue STEM careers and to support the teachers who are nurturing our future leaders.Continue reading
NCI PREVENT Cancer Program
The NCI PREVENT Cancer Program provides resources to move novel cancer-preventive chemical or biological agents and biomarkers towards clinical testing. Through a partnership with NCI, promising chemopreventive agents will be optimized and tested with the goals of filing an Investigational New Drug application with the U.S. FDA and entering the agent into clinical testing. Click here to learn more. The next deadline to apply is October 7, 2013.
NCI NExT Program
The NCI Experimental Therapeutics (NExT) Program consolidates NCI’s anticancer drug discovery and development resources in support of a goal-driven therapeutics pipeline. NCI partners with researchers from industry or academia to facilitate the milestone-driven progression of new anticancer drugs and imaging agents towards clinical evaluation and registration. Click here to learn more. The next deadline to apply is October 15, 2013.
The NCI Clinical Assay Development Program (CADP) provides resources for clinical assay validation to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. Click here to learn more. The next deadline to apply is October 15, 2013.
NCATS Therapeutics for Rare and Neglected Disease (TRND) Program
The National Center for Advancing Translational Sciences (NCATS) is pleased to announce an open opportunity to submit proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) program.
The TRND program supports preclinical and early clinical development of new drugs for rare and neglected tropical diseases by establishing collaborative partnerships with external researchers. Intended candidates for collaboration will be researchers who have promising leads and disease/target knowledge, but who lack the expertise or resources to fully develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations. TRND seeks to partner with academic laboratories, not-for-profit organizations, and for-profit companies. Foreign organizations are eligible to apply. TRND provides significant in-kind research support, but no direct external funding is available.Interested applicants may visit TRND on the web to learn more about the program, and can refer to the current NIH Guide Notice for more information.
Interested applicants must contact the TRND Solicitation Coordinator by email (TRND@mail.nih.gov) to initiate a pre-screening / Letter of Intent (LOI) process. Applications are made through the online proposal system, proposalCENTRAL (https://proposalcentral.altum.com/).
LOIs must be completed no later than September 16, 2013. Final applications are due by September 30, 2013.
Calling All Entrepreneurs & Stakeholders of Arizona’s Entrepreneurial Ecosystem.
Applications are now open for the Fall Arizona Innovation Challenge.Continue reading
The Biotechnology Industry Organization is proud to launch BIO Jobs, an online career resource where you can find the industry’s leading biotechnology employment opportunities all in one place.Continue reading
Announcing the 12th Annual BIO Investor Forum
The Biotechnology Industry Organization (BIO) is pleased to announce its advisory committee for the 12th Annual BIO Investor Forum, an international biotech investor conference focused on investment strategies for early stage and established private companies as well as emerging public companies. The event will take place October 8-9, 2013 at the Palace Hotel in San Francisco, Calif.
This esteemed group will help set the agenda and program for this year’s event which will assemble public and venture-stage growth companies, as well as top public and private equity investors, to explore investment trends and opportunities in life sciences.
Advisory Committee members include:
- Srini Akkaraju, MD, PhD, General Partner, Sofinnova Venture
- Katrine Bosley, (former) CEO, Avila Therapeutics
- Ashley Dombkowski, CBO, 23andMe
- Todd Foley, Managing Director, MPM Capital
- Gail Maderis, President & CEO, BayBio
- Janis Naeve, PhD, Managing Director, Amgen Ventures
- Bryan Roberts, PhD, Partner, Venrock
- Eugene Rozelman, Managing Director, Canaccord Genuity
- Francesco De Rubertis, PhD, Partner, Index Ventures
- Geeta Vemuri, PhD, VP, Head, Baxter Ventures
- Barbara Yanni, Vice President & Chief Licensing Officer, Merck
- Krishna Yeshwant, Partner, Google Ventures
In addition to panel discussions led by clinical thought leaders focusing on hot therapeutic areas, the conference features business roundtables focused on financing, investment and the latest M&A trends. BIO One-on-One Partnering™ will also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.
The BIO Investor Forum has become the ideal venue for investors and business development leaders to discuss financial and strategic business issues affecting investment in biotech companies, and explore potential partnerships and business collaborations to fuel research and development for promising innovation. Last year’s conference scheduled over 650 meetings. Nearly 80% of all requests were between biotech companies and investors. Furthermore, the event hosted nearly 110 late-stage private and emerging public company presentations.
The meeting attracts healthcare venture capital and public market investors and research analysts as well as business development executives from leading global pharmaceutical and biotechnology companies.
For more information, please go to bio.org/investorforum.
BIO Investor Forum Features
- BIO 1×1 Meetings
- Plenary Sessions and Workshops
- Company Presentations
- Networking Opportunities
2 New Montgomery Street
San Francisco, CA 94105
1.866.356.5155 (U.S.) or
John Sloan, Managing Director,
External Relations & Development, BIO
Achieve Your Business Goals and Drive Industry Conversation at AdvaMed 2013: The MedTech Conference Continue reading